Firms

Cape Fear BioCapital

Cape Fear BioCapital

capefearbiocap.com

Cape Fear BioCapital is an early-stage venture capital firm focused on building and financing therapeutics and related human-health technologies rooted in North Carolina. It writes first institutional checks at pre-seed and Seed and can also join later-stage syndicates for North Carolina companies. The firm works with university-linked science and founders to develop investable companies, recruit experienced leadership, establish proof-of-concept data and advance programs toward clinical development. Its published approach covers both multi-indication platforms and single-asset programs, emphasizing differentiated biology, novel modalities and companies approaching an investigational-new-drug filing. Published holdings span oncology drug discovery and RNA therapeutics, small-molecule cancer treatments, respiratory peptide medicines, cardiothoracic devices and AI-assisted cell and organoid manufacturing. A partnership with Parexel provides access to clinical-development and regulatory expertise through the Parexel Biotech Incubator. The firm’s legal management company is Cape Fear BioCapital Management Company, LLC; its Delaware FundI limited partnership and fund general partner are distinct entities. Moore Strategic Ventures anchors the fund, while Parexel and individual operators are investors and strategic partners rather than automatically firm employees.

Founded
—
Type
Venture capital

Funds1

  • Cape Fear BioCapital Fund I, LP—

    Cape Fear BioCapital’s inaugural Delaware venture capital limited partnership completed its final close, publicly announced September3,2026. The fund backs North Carolina therapeutics and related human-health companies at the earliest stages and selectively joins later-stage syndicates. The issuer reports seven investments and capacity for three to five additional startups. Moore Strategic Ventures is the anchor investor, with Parexel and biotech operators among the strategic investors. Exact final corpus is not stated in the close announcement. The September4 regulatory amendment reports USD8,995,000 sold against a USD9,500,000 offering with USD505,000 remaining; these are retained as dated regulatory figures rather than assumed final-close commitments.

Team

Operations and support

Dave OusteroutDave OusteroutGeneral Partner
Ed FieldGeneral Partner
Jimmy MeltonGeneral Partner
John P. BamforthStrategic adviser (reported April 2026; current membership unverified)
Robert J. SchotzingerPublished professional affiliation (specific role unverified)

Co-investing

Stephen Chambers

Investments